Literature DB >> 15591592

Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (Complex I) from rodent brain and a dopaminergic neuronal cell line.

Birgit Schilling1, Srinivas Bharath M M, Richard H Row, James Murray, Michael P Cusack, Roderick A Capaldi, Curt R Freed, Kedar N Prasad, Julie K Andersen, Bradford W Gibson.   

Abstract

Oxidative stress and mitochondrial dysfunction signify important biochemical events associated with the loss of dopaminergic neurons in Parkinson's disease (PD). Studies using in vitro and in vivo PD models or tissues from diseased patients have demonstrated a selective inhibition of mitochondrial NADH dehydrogenase (Complex I of the OXPHOS electron transport chain) that affects normal mitochondrial physiology leading to neuronal death. In an earlier study, we demonstrated that oxidative stress due to glutathione depletion in dopaminergic cells, a hallmark of PD, leads to Complex I inhibition via cysteine thiol oxidation (Jha et al. (2000) J. Biol. Chem. 275, 26096-26101). Complex I is a approximately 980-kDa multimeric enzyme spanning the inner mitochondrial membrane comprising at least 45 protein subunits. As a prerequisite to investigating modifications to Complex I using a rodent disease model for PD, we developed two independent rapid and mild isolation procedures based on sucrose gradient fractionation and immunoprecipitation to isolate Complex I from mouse brain and a cultured rat mesencephalic dopaminergic neuronal cell line. Both protocols are capable of purifying Complex I from small amounts of rodent tissue and cell cultures. Blue Native gel electrophoresis, one-dimensional and two-dimensional SDS-PAGE were employed to assess the purity and composition of isolated Complex I followed by extensive mass spectrometric characterization. Altogether, 41 of 45 rodent Complex I subunits achieved MS/MS sequence coverage. To our knowledge, this study provides the first detailed mass spectrometric analysis of neuronal Complex I proteins and provides a means to investigate the role of cysteine oxidation and other posttranslational modifications in pathologies associated with mitochondrial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591592     DOI: 10.1074/mcp.M400143-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  21 in total

1.  ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import.

Authors:  Quan Li; Christine Vande Velde; Adrian Israelson; Jing Xie; Aaron O Bailey; Meng-Qui Dong; Seung-Joo Chun; Tamal Roy; Leah Winer; John R Yates; Roderick A Capaldi; Don W Cleveland; Timothy M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 2.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 3.  Protein-protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches.

Authors:  Armand G Ngounou Wetie; Izabela Sokolowska; Alisa G Woods; Urmi Roy; Katrin Deinhardt; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2013-04-12       Impact factor: 9.261

4.  Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.

Authors:  Rajeshwari D Koilkonda; Hong Yu; Tsung-Han Chou; William J Feuer; Marco Ruggeri; Vittorio Porciatti; David Tse; William W Hauswirth; Vince Chiodo; Sanford L Boye; Alfred S Lewin; Martha Neuringer; Lauren Renner; John Guy
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

5.  Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.

Authors:  Brandi L Rollins; Ling Morgan; Brooke E Hjelm; Adolfo Sequeira; Alan F Schatzberg; Jack D Barchas; Francis S Lee; Rick M Myers; Stanley J Watson; Huda Akil; Steven G Potkin; William E Bunney; Marquis P Vawter
Journal:  Mol Neuropsychiatry       Date:  2017-11-30

6.  Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation.

Authors:  Maureen O Ripple; Namjoon Kim; Roger Springett
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

7.  A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease.

Authors:  Donna W Lee; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Julie K Andersen
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

8.  Reactive oxygen species regulation by AIF- and complex I-depleted brain mitochondria.

Authors:  Shankar J Chinta; Anand Rane; Nagendra Yadava; Julie K Andersen; David G Nicholls; Brian M Polster
Journal:  Free Radic Biol Med       Date:  2009-04-01       Impact factor: 7.376

9.  Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.

Authors:  Steven R Danielson; Jason M Held; Birgit Schilling; May Oo; Bradford W Gibson; Julie K Andersen
Journal:  Anal Chem       Date:  2009-09-15       Impact factor: 6.986

10.  A density-based proteomics sample fractionation technology: folate deficiency induced oxidative stress response in liver and brain.

Authors:  Wenkui Lan; Jayita Guhaniyogi; Marc J Horn; Jun Q Xia; Beverly Graham
Journal:  J Biomol Tech       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.